Rivals Hologic (NSDQ:HOLX) and C.R. Bard came to terms on a legal settlement, closing the books on a years-old patent infringement lawsuit by swapping some assets.
Hologic revealed in in its latest report that it had acquired SenoRx’s Contura breast cancer radiation therapy assets as part of a settlement with C.R. Bard, which acquired SenoRx in 2010. Hologic did not reveal the terms of the settlement.
The settlement puts to bed an ongoing patent infringement lawsuit that has roots as far back as 2008, when Hologic accused SenoRx of infringing 2 patents covering Hologic’s MammoSite breast cancer radiation therapy system with its Contura device.
Hologic in December 2009 lost that battle, and said that it planned to appeal the decision. In July 2009, C.R. Bard nabbed up SenoRx for $200 million and in February 2012 filed a lawsuit against Hologic.
In May 2013 the parties settled their complaints with SenoRx’s disputed Contura assets now belonging to Hologic.
